Ad5FGF-4 gene Adenoviral intracoronary infusion of human angiogenic fibroblast growth factor-4 (FGF-4),Primary Endpoint: Exercise tolerance test time compared with baseline at 12 weeks, 6 months and 1 year. Secondary Endpoints: Time to number of patients with coronary events and death at 12 months Time to ST depression, angina, and quality of life parameters,AGENT III: 12 week results,Presented at TCT 2004,Placebo,Low-dose,High-dose,415 patients with CCS Class 2-4 angina not in need of urgent revascularization,AGENT III Trial: 12 week results,The 12-week results show no difference between the three groups in the primary endpoint mean change in exercise duration from baseline,seconds,TCT 2004,Mean change in exercise duration from baseline to 12 weeks p=ns,AGENT III: 12-week results,415 people with stable angina were randomized to receive placebo or a low- or high-dose intracoronary infusion of an adenoviral gene for fibroblast growth factor-4 (FGF-4) before the trial was stopped earlier this year by the data safety and monitoring board The 12-week results show no difference between the three groups in the primary endpoint mean change in exercise duration from baseline.,TCT 2004,